Traditional drug spending in the U.S. has surpassed specialty drug spending, and the primary force behind this trend is GLP-1 receptor agonists. These incretin-based therapies are transforming both the clinical and economic landscapes, from diabetes to obesity.
In this episode of the Center for Pharmacy Practice Excellence’s VerifiedRx podcast, host Tori Richie, Senior Consulting Director of Intelligence at Sg2 is joined by Vizient colleagues Stacy Lauderdale, AVP of Evidence-Based Medicine, Heather Pace, Senior Clinical Manager of Ambulatory Care, and Emily Fitt, I...
Traditional drug spending in the U.S. has surpassed specialty drug spending, and the primary force behind this trend is GLP-1 receptor agonists. These incretin-based therapies are transforming both the clinical and economic landscapes, from diabetes to obesity.
In this episode of the Center for Pharmacy Practice Excellence’s VerifiedRx podcast, host Tori Richie, Senior Consulting Director of Intelligence at Sg2 is joined by Vizient colleagues Stacy Lauderdale, AVP of Evidence-Based Medicine, Heather Pace, Senior Clinical Manager of Ambulatory Care, and Emily Fitt, Intelligence Consultant at Sg2. They delve into a comprehensive discussion on GLP-1s, covering topics from telehealth services and patient management strategies to the unique attributes that set these therapies apart.
Grab your coffee and get comfortable. This isn’t just a conversation; it’s a front-row seat to how GLP-1s are reshaping the future of obesity management.
Guest speakers:
Stacy Lauderdale, Pharm.D, BCPS
Associate Vice President
Vizient Center for Pharmacy Practice Excellence
VerifiedRx Host
Heather Pace, Pharm.D
Sr. Clinical Manager of Ambulatory Care,
Vizient Center for Pharmacy Practice Excellence
Emily Fitt, MHA, MPH
Consultant
Sg2
Host:
Tori Richie
Senior Consulting Director, Intelligence
Sg2
Sg2 Perspectives Host
Show Notes:
[02:24-04:50] How GLP-1 medications differ from traditional treatments and shift from use in diabetes to obesity management
[04:51-05:54] The most common side effects of GLP-1 therapies and how clinicians can effectively manage patients
[05:55-08:49] Treatment teams for obesity management and the role of the pharmacist in the management of GLP-1 medications
[08:50-10:51] Challenges providers face integrating GLP-1 medications into practice
[10:16-13:20] Quality or outcome concerns with individuals who receive GLP-1 medications from telehealth providers
[13:21-15:01] Trends shaping this landscape
[15:02-21:14] Best practices that providers should deploy
Subscribe Today!
Apple Podcasts
Amazon Podcasts
Spotify
Android
RSS Feed
View more
